Thomas Shrader News Today

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript March 28, 2024 INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.58. INMB isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, greetings and welcome […]

Operator: Ladies and gentlemen. Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2023 Conference Call and Webcast. At this time, all participants are in a listen-only mode.

Are penny stocks a must-have or a must-avoid? Well, that depends on who you ask. There’s no middle ground when it comes to these tickers trading for less than $5 per share; those on the Street are either fans or harsh critics. Both sides make sense. The naysayers argue that the bargain price is just too good to be true, with it potentially indicating there are problems hiding beneath the surface like weak fundamentals or overwhelming headwinds. However, the investors that are pro-penny st...

(Bloomberg) -- Noubar Afeyan became a billionaire backing Moderna Inc., the dark horse biotech firm that became a household name due to its lifesaving Covid vaccine. He just added to his fortune after another one of his long-shot bets quintupled in value.Most Read from BloombergSwitzerland Blocks Sale of Leopard 1 Tanks Bound for UkraineA $100 Billion Wealth Migration Tilts US Economy’s Center of Gravity SouthPutin Claims He’s Back in Control. Russia’s Elite Isn’t Sur...

New Drug for Bone Growth Disorder Improves Height Velocity

Trial Results of New Pneumococcal Vaccine Compelling

Follow along live as the No. 13 FSU Seminoles finish the 2022 college football season vs. the Oklahoma Sooners in the Cheez-It Bowl in Orlando.

A stellar fourth quarter and a 418-yard game from Jordan Travis result in FSU's win.

The FSU Seminoles (7-3) face the Louisiana Ragin Cajuns (5-5) on Saturday, November 19, 2022 at Doak Campbell Stadium in Tallahassee, Florida.

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ:GANX) from $30 to $10. BTIG analyst Thomas Shrader maintained a Buy rating on the s...